AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $37.50.
Several research firms recently weighed in on AGMB. B. Riley Financial initiated coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a "buy" rating and a $34.00 price target on the stock. HC Wainwright reiterated a "buy" rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Piper Sandler began coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an "overweight" rating and a $60.00 target price on the stock. Wall Street Zen downgraded AgomAb Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, September 27th. Finally, Johnson Rice reissued a "buy" rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st.
Check Out Our Latest Report on AGMB
AgomAb Therapeutics Trading Down 1.7%
AGMB stock opened at $5.82 on Thursday. The firm has a 50 day moving average price of $9.02 and a 200-day moving average price of $11.63. AgomAb Therapeutics has a 52-week low of $5.50 and a 52-week high of $17.82.
Insider Transactions at AgomAb Therapeutics
In other news, CEO Tim Jasper Knotnerus purchased 6,000 shares of the company's stock in a transaction that occurred on Monday, October 5th. The shares were bought at an average price of $8.48 per share, for a total transaction of $50,880.00. Following the purchase, the chief executive officer directly owned 16,823 shares in the company, valued at approximately $142,659.04. This trade represents a 55.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Pierre Kemula acquired 10,000 shares of the business's stock in a transaction that occurred on Tuesday, October 6th. The shares were purchased at an average cost of $8.59 per share, for a total transaction of $85,900.00. Following the completion of the transaction, the chief financial officer directly owned 10,000 shares in the company, valued at $85,900. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 70,980 shares of company stock valued at $549,262 in the last quarter.
AgomAb Therapeutics Company Profile
(
Get Free Report)
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company's pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn's disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AgomAb Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AgomAb Therapeutics wasn't on the list.
While AgomAb Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.